Chimerix (CMRX)
(Delayed Data from NSDQ)
$3.39 USD
-0.09 (-2.59%)
Updated Jan 2, 2025 04:00 PM ET
After-Market: $3.39 0.00 (0.00%) 7:36 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CMRX 3.39 -0.09(-2.59%)
Will CMRX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for CMRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMRX
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
CMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Top Estimates
Other News for CMRX
A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts
Chimerix Receives ‘Buy’ Rating from Edward White on Promising Drug Development and Strong Financial Outlook
Promising Outlook for Chimerix: Strategic Developments and Financial Strength Justify Buy Rating
Chimerix submits dordaviprone NDA for accelerated approval
Chimerix submits dordaviprone NDA for accelerated approval